Lux Biosciences Receives Acceptance of Luveniq(TM) MAA Filing from European Medicines Evaluation Agency

JERSEY CITY, N.J.--(BUSINESS WIRE)--Lux Biosciences, Inc. today announced that the European Medicines Agency (EMA) has accepted the filing of the company’s Marketing Authorization Application (MAA) for the company’s lead product, Luveniq™ (LX211; oral voclosporin) for the treatment of noninfectious uveitis involving the intermediate or posterior segments of the eye. Lux previously announced the filing of both the MAA and U.S. New Drug Application (NDA) for LX211, which has received Orphan Drug designation in both regions, on February 4, 2010.